Showing 1 - 10 of 34,550
Following the Global Pharma Health Fund e.V. Minilab® protocol, we find 9.88% of samples have less than 80% of the correct active ingredient and 41.5% of these failures are counterfeits. Both product registration and chain affiliation of retailers are strong indicators of higher probability to...
Persistent link: https://www.econbiz.de/10012460586
Both samples convey a consistent message that certification agencies deliver useful information for foreign websites and online consumers. Further, while these findings confirm the FDA warning against rogue websites, they do suggest that a blanket ban against all foreign websites may deny...
Persistent link: https://www.econbiz.de/10012460704
Focusing on 8 drug types on the WHO-approved medicine list, we constructed an original dataset of 899 drug samples from 17 low- and median-income countries and tested them for visual appearance, disintegration, and analyzed their ingredients by chromatography and spectrometry. Fifteen percent of...
Persistent link: https://www.econbiz.de/10012461804
Persistent link: https://www.econbiz.de/10010416365
Experts claim that some Indian drug manufacturers cut corners and make substandard drugs for markets with non-existent, under-developed or emerging regulatory oversight, notably Africa. This paper assesses the quality of 1470 antibiotic and tuberculosis drug samples that claim to be made in...
Persistent link: https://www.econbiz.de/10013312516
Experts claim that some Indian drug manufacturers cut corners and make substandard drugs for markets with non-existent, under-developed or emerging regulatory oversight, notably Africa. This paper assesses the quality of 1470 antibiotic and tuberculosis drug samples that claim to be made in...
Persistent link: https://www.econbiz.de/10010950809
Persistent link: https://www.econbiz.de/10009509405
Persistent link: https://www.econbiz.de/10009548834
Persistent link: https://www.econbiz.de/10009530131
Persistent link: https://www.econbiz.de/10010345596